An NCI-designated Comprehensive Cancer Center

Larry W. Kwak, M.D., Ph.D.

Hematologist - Oncologist; Dr. Michael Friedman Professor in Translational Medicine
Clinical Expertise
Research Focus
  • Immunology
  • Cancer vaccines
Appointments
Vice President and Deputy Director, Comprehensive Cancer Center; Director, Toni Stephenson Lymphoma Center; Professor, Department of Hematology & Hematopoietic Cell Transplantation

Clinical Teams

  • Lymphoma
  • Hematology & Hematopoietic Cell Transplantation
Larry W. Kwak, M.D., Ph.D., is a world-renowned physician and scientist who has pioneered breakthrough innovations in immunology and cancer vaccines. He joined City of Hope in April 2015, following a decade of leadership in lymphoma and myeloma research and treatment at M.D. Anderson Cancer Center in Houston.
 
Named one of TIME magazine's "100 Most Influential People" in 2010, Dr. Kwak is the deputy director of City of Hope's comprehensive cancer center, director of the Toni Stephenson Lymphoma Center within the Hematologic Malignancies and Stem Cell Transplantation Institute and is endowed with the title of the Dr. Michael Friedman Professor in Translational Medicine.
 
Passionate about harnessing the body's immune system to battle cancer, Dr. Kwak's interest in the field was sparked by a high school mentor and has continued for nearly three decades. He takes special pride in his ability to rapidly translate basic research into human clinical trials, making him an ideal fit for the City of Hope environment.
 

Locations

City of Hope Comprehensive Cancer Center, 1500 East Duarte Road

Duarte, CA 91010

In The News
An Expert's Voice
Larry Kwak

CAR T cell therapy targeting new receptor proves effective for relapsed CAR T patients

City of Hope News

First chimeric antigen receptor (CAR) T cell therapy targeting B cell-activating factor receptor (BAFF-R) eradicates blood cancers that relapsed after CD19 CAR T therapies

red and white blood cells illustration stock - large hi res

City of Hope investigators present breakthrough research at 60th American Society of Hematology meeting